A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

A Review of Late-Stage HIV Antiretroviral Candidates at IDWeek 2017

1 of 6
Next >

IDWeek Roundup

In the world of HIV drug development, several noteworthy candidates are quickly approaching potential U.S. Food and Drug Administration approval. While it's still far too soon to start thinking about regulatory approval of vaccines and more nascent cure research, the results of several large clinical trials on new antiretroviral therapies have been announced, including data on long-acting injectable solutions and new combination treatments packed into a single pill.

In the world of HIV drug development, several noteworthy candidates are quickly approaching potential U.S. Food and Drug Administration approval. While it's still far too soon to start thinking about regulatory approval of vaccines and more nascent cure research, the results of several large clinical trials on new antiretroviral therapies have been announced, including data on long-acting injectable solutions and new combination treatments packed into a single pill.

These results were presented at a smattering of sessions at IDWeek 2017, Oct. 4-8. Here, we highlight major findings on late-stage antiretroviral candidates, including those discussed in talks by Eric Daar, M.D., Harbor-UCLA Medical Center; Paul Sax, M.D., Brigham and Women's Hospital; and Brinda Emu, M.D., Yale School of Medicine.

Image: Attendees discuss a poster presentation at IDWeek 2017 (Credit: Infectious Diseases Society of America).